查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950479

HAE治療市場按治療機制、產品類型、給藥途徑、最終用戶、患者年齡層和分銷管道分類，全球預測，2026-2032年

HAE Treatments Market by Therapy Mechanism, Product Type, Route Of Administration, End User, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，HAE 治療市場價值將達到 42.5 億美元，到 2026 年將成長至 46.9 億美元，到 2032 年將達到 98.5 億美元，複合年成長率為 12.75%。

關鍵市場統計數據
基準年 2025 42.5億美元
預計年份：2026年 46.9億美元
預測年份 2032 98.5億美元
複合年成長率 (%) 12.75%

簡要概述遺傳性血管性水腫 (HAE)治療方法、監管和商業性趨勢的演變如何重塑治療護理和相關人員的優先事項。

遺傳性血管性水腫 (HAE) 已從一種鮮為人知的罕見疾病發展成為治療方法、醫療服務模式和商業策略等各個領域創新的焦點。近期科學的進步拓展了可行的分子治療方法範圍，同時，診斷意識的提高和患者權益倡導力度的加強，也使該疾病成為臨床優先關注的領域和支付方關注的重點。本文概述了塑造 HAE 格局的多方面趨勢，包括治療方法的多樣化、醫療環境的變化以及價值從研發者和經銷商向患者和醫療服務提供者的重新分配。

科學突破、醫療服務創新和商業性結構調整如何共同改變遺傳性血管性水腫 (HAE) 的治療選擇和患者就醫途徑

由技術突破、患者期望的不斷變化以及醫療服務體系的結構性變革所驅動的遺傳性血管性水腫（HAE）治療格局正在經歷一場變革。在治療方面，基因介入和單株療法等精準醫療方法的出現，與生物製藥和小分子藥物的進展相輔相成。口服受體拮抗劑和催化激肽釋放酶抑制劑為臨床醫生和患者提供了更多實用選擇，而長效製劑則提供了更便捷的給藥方式，並提高了患者的依從性。

評估關稅和貿易政策變化對遺傳性血管性水腫治療的多方面供應鏈、臨床開發和獲取途徑的影響

提案的2025年貿易政策調整和關稅措施，為依賴全球分散供應鏈的治療方法帶來了不確定性，其累積影響值得策略性關注。原料藥、生物中間體、包裝組件和專用設備在最終組裝前通常需要經過多個司法管轄區，而進口關稅和日益嚴格的邊境管制正在推高投入成本並延長前置作業時間。實際上，這些情況迫使企業重新評估籌資策略、庫存管理政策和定價模式，以維持醫療服務的連續性並履行對醫療機構的合約義務。

將治療機制、給藥途徑、分銷管道和患者群體與策略發展和商業化要務聯繫起來的詳細細分分析

細分市場分析揭示了影響研發重點和商業性策略的細微機會和限制因素，這些因素涵蓋了治療機制、產品類型、給藥途徑、分銷管道、終端用戶和患者群體。基於治療機制，可得出三大叢集：緩激肽受體拮抗劑（包括已上市藥物如icatibant以及包括口服受體拮抗劑在內的未來在研拮抗劑產品線）、C1抑製劑替代療法（包括血漿衍生產品和重組產品，以及基因治療和單克隆抗體療法等未來機制）和激肽釋放酶抑製劑（以ecallantide和代表Sbant 等抑製劑為新的催化藥物）。每種作用機制都對應著獨特的臨床特徵和生產流程，這為市場定位策略和循證醫學證據生成計劃提供了基礎。

區域監管差異、支付方框架和醫療保健基礎設施將如何影響遺傳性血管性水腫治療的差異化准入策略和商業化路徑

區域趨勢將對HAE治療全過程的監管時間表、報銷框架、生產策略和患者就醫途徑產生重大影響。在美洲，監管參與策略需要與國家和州級機構協調，同時也需要一個重視價值證明、准入計畫和病患支援基礎設施的支付方環境。在該地區運營的製造商受益於強大的臨床試驗網路和患者權益倡導組織，但也面臨著價格壓力和複雜的支付方合約要求，這些因素會影響產品上市順序和支持性投資。

檢驗市場上遺傳性血管性水腫治療藥物的競爭性開發商、製造商和分銷商之間的策略、營運和商業性差異化因素

生物製藥企業在血小板聚集性腫瘤（HAE）領域的競爭格局呈現出多元化的特點，既有成熟的生物製藥企業，也有致力於研發新型作用機制的新興生物技術公司，以及專注於治療複雜慢性疾病的專業經銷商。領先的研發企業致力於透過基於作用機制的優勢、改進的給藥途徑和延長作用持續時間來打造差異化的產品系列。策略合作、授權協議和有針對性的收購仍然是加速臨床開發、擴大生產能力以及在重點區域站穩腳跟的常用策略。

為確保持續可近性，開發商和相關人員可採取切實可行的策略措施：結合臨床差異化、供應彈性以及基於證據的支付方參與

為了在遺傳性血管性水腫（HAE）領域創造長期價值，產業領導者應採取平衡的策略，同時兼顧臨床差異化和營運韌性。優先投資於能夠提升患者便利性的治療方案，例如口服拮抗劑、皮下製劑和長效預防藥物，可望顯著提高藥物的接受度和依從性。但這些努力必須輔以嚴謹的證據生成，以量化真實世界的獲益，並與支付方的終點指標保持一致。

採用嚴謹的混合方法，整合臨床醫師訪談、監管審查、產品線梳理和情境分析，得出檢驗的研究結果。

本報告的研究整合了一級資訊來源和二級資訊來源，並採用結構化且透明的調查方法，旨在確保研究的有效性和相關性。第一手資料包括對臨床醫生、臨床營運總監、支付方、專科藥房高管以及在HAE管理方面經驗豐富的行業專家進行的半結構式訪談，從而提供了關於實施障礙、證據預期和患者需求的實用觀點。一級資訊來源資料是對公開資訊的全面回顧，包括同行評審文獻、監管指南、臨床試驗註冊資訊、治療指南以及關鍵治療領域的安全性和有效性數據。

一項前瞻性的綜合分析將臨床創新、營運準備和符合支付方需求的證據生成聯繫起來，為HAE治療方法提供永續的推廣途徑。

遺傳性血管性水腫 (HAE) 的治療格局正處於轉折點，治療方法創新、護理模式的轉變以及外部政策壓力正在重新定義價值的創造和傳遞方式。新的作用機制和改良的製劑正在拓展臨床選擇，而分銷和護理服務的創新則提高了治療的便利性和連續性。然而，供應鏈的複雜性、監管機構對長期證據的要求以及支付方對可證實療效的需求等實際操作因素，將決定哪些創新能夠獲得持續應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療機制分類的HAE治療市場

  • 緩激肽受體拮抗劑
  • C1抑制劑替代療法
    • 血漿來源的C1抑制劑
    • 重組C1抑制劑
  • 激肽釋放酶抑制劑
    • 依卡蘭肽
    • 拉那德魯單抗

9. HAE治療市場依產品類型分類

  • 一經請求
  • 預防

第10章 依給藥途徑分類的HAE治療市場

  • 靜脈注射
  • 皮下注射

第11章 依最終使用者分類的 HAE 治療市場

  • 診所
  • 家庭醫療保健
  • 醫院

第12章 依患者年齡層別分類的HAE治療市場

  • 成人版
  • 老年人
  • 兒童

第13章 HAE治療市場按分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 專科藥房

第14章 HAE治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 HAE治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國 HAE 治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 美國 HAE 治療市場

第18章 中國 HAE 治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adverum Biotechnologies, Inc.
  • Akari Therapeutics plc
  • Alnylam Pharmaceuticals, Inc.
  • Argenx SE
  • AstraZeneca plc
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring GmbH
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Homology Medicines, Inc.
  • IBio, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pharming Group NV
  • Regeneron Pharmaceuticals, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-4F7A6D4FD88E

The HAE Treatments Market was valued at USD 4.25 billion in 2025 and is projected to grow to USD 4.69 billion in 2026, with a CAGR of 12.75%, reaching USD 9.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.25 billion
Estimated Year [2026] USD 4.69 billion
Forecast Year [2032] USD 9.85 billion
CAGR (%) 12.75%

A concise overview of the evolving therapeutic, regulatory, and commercial dynamics reshaping hereditary angioedema care and stakeholder priorities

Hereditary angioedema (HAE) has evolved from a narrowly understood rare disease to a focal point for innovation across therapeutic modalities, care delivery models, and commercial strategies. Recent scientific advances have broadened the range of viable molecular approaches, while improvements in diagnostic awareness and patient advocacy have sharpened clinical priority and payer attention. This introduction frames the multi-dimensional dynamics shaping the HAE landscape: therapeutic diversification, changing care settings, and a redistribution of value across stakeholders from developers and distributors to patients and providers.

Clinical practice is shifting toward more individualized regimens that balance acute management and long-term prophylaxis, and this evolution is catalysed by therapies that reduce attack frequency and severity with different safety and administration profiles. Concurrently, regulatory agencies are applying adaptive review pathways and demanding deeper real-world evidence, which is altering development timelines and go-to-market planning. In parallel, commercial models are responding to new product formats and channels of distribution that enable home administration and patient-centered support services.

Taken together, these forces are converging to create an environment in which innovation is judged not only by clinical efficacy but also by route of administration, treatment durability, and integration with patient support and digital health platforms. This introduction sets the stage for a detailed analysis of the transformative shifts, segmentation dynamics, regional nuances, and strategic imperatives that follow.

How scientific breakthroughs, care delivery innovations, and commercial realignments are jointly transforming treatment options and patient access in hereditary angioedema

The HAE treatment landscape is undergoing transformative shifts driven by technological breakthroughs, evolving patient expectations, and structural changes in care delivery. On the therapeutic front, the emergence of precision approaches such as gene-based interventions and monoclonal modalities is complementing improvements in biologic and small-molecule programs. Oral receptor antagonists and catalytic kallikrein inhibitors are expanding the practical choices available to clinicians and patients, and extended half-life formulations are increasing dosing convenience and adherence potential.

Care delivery and distribution are being reconfigured as more therapies become suitable for subcutaneous or at-home administration; this is enabling a shift away from hospital-centric models toward home healthcare and specialty pharmacy engagement. Telemedicine and remote monitoring are reinforcing that trend, enabling clinicians to titrate prophylactic regimens with more frequent, lower-friction touchpoints. At the same time, payer expectations demand robust real-world evidence to demonstrate durable outcomes and cost offsets, which is accelerating investment in longitudinal registries and digital endpoints.

Industrial dynamics are also changing. Biotech innovators focused on differentiated mechanisms are increasingly partnering with established manufacturers to scale production and navigate complex biologics supply chains. Meanwhile, contract manufacturing capacity and cold-chain logistics are being prioritized to support recombinant proteins and other complex modalities. These shifts collectively favor developers who can integrate clinical differentiation with pragmatic deployment strategies, delivering therapies that meet clinical needs while aligning with reimbursement and distribution realities.

Assessing the multifaceted supply chain, clinical development, and access implications of tariff shifts and trade policy changes affecting hereditary angioedema therapeutics

Trade policy shifts and proposed tariff measures in 2025 have created an environment of uncertainty for therapies dependent on globally distributed supply chains, and their cumulative effects merit strategic attention. Active pharmaceutical ingredients, biologic intermediates, packaging components, and specialized devices often travel across multiple jurisdictions before final assembly, and any increase in import duties or border controls can amplify input costs and extend lead times. In practice, these dynamics pressure companies to reassess sourcing strategies, inventory policies, and pricing models to preserve continuity of care and contractual commitments to providers.

Beyond direct cost implications, tariff-driven disruptions can trigger secondary consequences for clinical development timelines and market readiness. Delays or cost escalations in sourcing critical reagents or finished dosage forms can complicate trial supply management and regulatory filings, particularly for sponsors relying on single-source suppliers or concentrated manufacturing footprints. Moreover, higher cross-border transaction costs may incentivize onshoring or nearshoring of manufacturing capacity, which can reduce exposure to tariff volatility but requires capital investment and time to operationalize.

Payers and providers are sensitive to changes that affect total cost of care, so commercial strategies must anticipate how incremental supply chain costs could be expressed through contracting provisions, rebate structures, or patient support funding. Firms can mitigate exposure by diversifying suppliers, securing long-term procurement agreements, investing in regional manufacturing nodes, and building scenario models that quantify the operational impact of tariff scenarios. Proactive engagement with trade advisors, customs authorities, and supply chain partners will be essential to preserving product availability and maintaining trust with clinicians and patients during periods of policy-driven disruption.

A granular segmentation synthesis linking therapeutic mechanisms, administration routes, channels, and patient cohorts to strategic development and commercialization imperatives

Segmentation analysis reveals nuanced opportunities and constraints across therapeutic mechanism, product type, route of administration, distribution channel, end user, and patient age group, each shaping development priorities and commercial approaches. Based on therapy mechanism, three clusters stand out: bradykinin receptor antagonists, which encompass established agents such as icatibant and a pipeline of future antagonists including oral receptor antagonists; C1 inhibitor replacement therapies, which include plasma derived and recombinant products alongside future mechanisms such as gene therapy and monoclonal antibody approaches; and kallikrein inhibitors, represented by agents like ecallantide and lanadelumab as well as emerging catalytic inhibitors. Each mechanism implies a distinct clinical profile and manufacturing pathway, informing positioning strategies and evidence generation plans.

Product type segmentation differentiates on-demand interventions from prophylactic strategies and highlights a category of future product types that prioritize extended half-life therapies and long-acting prophylactics. Route of administration remains a pivotal axis: intravenous formulations retain a role for acute settings while subcutaneous options expand suitability for outpatient and home use, and projected oral routes are poised to change adherence and uptake dynamics. Distribution channel distinctions include hospital, retail, and specialty pharmacies, with a growing emphasis on direct-to-patient models that streamline access for chronic prophylaxis.

End user segmentation underscores the different care settings where value is realized: clinics and hospitals will remain centers for acute care and complex administration, while home healthcare and telemedicine are scaling as vehicles for routine prophylaxis and remote management. Patient age group segmentation ranges from pediatric and adult to geriatric cohorts, with emerging attention to adolescent populations that influence dosing, formulation, and support program design. Integrated segmentation insight indicates that successful products will align mechanism and formulation with the most appropriate route and channel, supported by stakeholder-specific evidence that addresses clinical outcomes, quality of life, and operational feasibility.

How regional regulatory diversity, payer frameworks, and healthcare infrastructure shape differentiated access strategies and commercialization pathways for hereditary angioedema treatments

Regional dynamics exert a strong influence on regulatory timelines, reimbursement frameworks, manufacturing strategy, and patient access across the HAE continuum. In the Americas, regulatory engagement strategies must navigate centralized and national agencies alongside a payer environment that places emphasis on value demonstration, access programs, and patient support infrastructure. Manufacturers operating in this region benefit from robust clinical trial networks and strong patient advocacy groups, but they also face negotiated pricing pressures and complex payer contracting requirements that shape launch sequencing and support investments.

Europe, Middle East & Africa presents a heterogeneous landscape where centralized regulatory mechanisms coexist with national health technology assessment processes that vary in evidentiary expectations and threshold definitions. Manufacturers need adaptable evidence packages and pricing strategies that respect country-specific procurement mechanisms, and partnerships with regional distributors and specialty pharmacies are often necessary to ensure continuity of care across diverse health systems. In several markets, expanded access and early access mechanisms create pathways for novel therapies to reach patients sooner, provided that stakeholders can commit to post-authorization evidence generation.

Asia-Pacific encompasses a broad range of market maturity, from well-established regulatory systems to emerging markets with growing diagnostic and treatment capacity. Local manufacturing and regulatory harmonization efforts can facilitate faster onboarding, while variations in reimbursement and out-of-pocket payment structures necessitate differentiated access models and patient assistance programs. Across all regions, supply chain resilience, tailored payer engagement, and culturally adapted patient support services are central to achieving sustainable access and adoption.

An examination of strategic, operational, and commercial differentiators among developers, manufacturers, and distributors competing in hereditary angioedema therapeutics

Competitive dynamics in HAE are characterized by a mix of well-established biologics manufacturers, emerging biotechnology firms pursuing novel mechanisms, and specialty distributors focused on complex chronic therapies. Leading developers are concentrating on differentiating their portfolios through mechanism-driven advantages, improved administration routes, and extended durability of effect. Strategic collaborations, licensing agreements, and targeted acquisitions remain common tactics to accelerate clinical development, expand manufacturing capacity, and secure commercial footholds in priority geographies.

Operational excellence in manufacturing, cold-chain logistics, and supply continuity is a competitive differentiator, particularly for recombinant and plasma-derived products. Companies that invest in scalable biologics production and robust quality systems can shorten time-to-market and reduce operational risk. Equally important is the ability to generate high-quality real-world evidence through registries and outcomes partnerships that demonstrate long-term benefits, which supports payer negotiations and formulary positioning.

Commercially, firms are refining patient support ecosystems that include adherence programs, nurse-led education, and financial assistance designed to improve persistence and reduce barriers to access. Distribution strategies that leverage specialty pharmacies and direct-to-patient fulfillment can enhance retention for prophylactic therapies, while hospital-centric channels remain essential for acute care products. Overall, success is trending toward organizations that combine scientific differentiation with pragmatic operational and commercial execution.

Practical strategic moves for developers and stakeholders that combine clinical differentiation, supply resilience, and evidence-driven payer engagement to secure durable access

Industry leaders should adopt a balanced strategy that simultaneously advances clinical differentiation and operational resilience to capture long-term value in the HAE landscape. Prioritizing pipeline investments in modalities that improve patient convenience-such as oral antagonists, subcutaneous formulations, and long-acting prophylactics-can materially increase uptake and adherence, but these efforts must be paired with rigorous evidence generation that quantifies real-world benefit and aligns with payer endpoints.

From an operational perspective, diversify supplier networks for critical biological inputs and consider regional manufacturing investments to reduce exposure to cross-border policy shifts and tariff volatility. Strengthen relationships with specialty pharmacies, home healthcare providers, and telemedicine platforms to create integrated care pathways that support at-home administration and remote monitoring. In parallel, invest in patient support services that address financial toxicity, education, and adherence, as these programs are often decisive in payer discussions and patient retention.

Engage proactively with regulators and health technology assessors to co-develop pragmatic evidence plans that utilize registries, patient-reported outcomes, and claims data to demonstrate long-term value. Explore risk-sharing and outcomes-based contracting where appropriate, and ensure commercial teams are equipped with health economic models and real-world evidence summaries to support negotiations. Finally, cultivate partnerships and licensing arrangements to accelerate development where internal capabilities are constrained, and maintain flexibility to pivot prioritization in response to emergent clinical or policy signals.

A rigorous mixed-methods approach integrating clinician interviews, regulatory review, pipeline mapping, and scenario analysis to produce validated insights

The research underpinning this report synthesizes primary and secondary sources through a structured, transparent methodology designed to ensure validity and relevance. Primary inputs included semi-structured interviews with clinicians experienced in HAE management, clinical operations leaders, payers, specialty pharmacy executives, and industry experts who provided practical perspectives on adoption barriers, evidence expectations, and patient needs. Secondary research encompassed a review of peer-reviewed literature, regulatory guidance, clinical trial registries, treatment guidelines, and published safety and efficacy data for key therapeutic classes.

Pipeline mapping and mechanism-of-action analysis were used to categorize investigational therapies and to assess clinical differentiation potential. Distribution and channel analysis combined publicly available formulary and reimbursement policies with interviews of distribution stakeholders to identify operational constraints and emerging direct-to-patient models. Scenario analysis was employed to evaluate the potential operational impacts of trade policy shifts, supply disruptions, and changes in reimbursement practices, with mitigation strategies developed through iterative expert validation.

Data triangulation and cross-validation techniques were applied to reconcile disparate inputs and to identify consensus viewpoints versus areas of divergence. Throughout, ethical standards and confidentiality commitments governed interactions with informants, and methodological limitations are acknowledged where evidence remains nascent or contested, particularly regarding long-term outcomes for novel modalities.

A forward-looking synthesis that links clinical innovation, operational readiness, and payer-aligned evidence generation to sustainable adoption pathways for HAE therapies

The hereditary angioedema ecosystem is at an inflection point where therapeutic innovation, shifting care models, and external policy pressures converge to redefine how value is created and delivered. Novel mechanisms and formulation improvements are expanding clinical choices, while distribution and care delivery innovations are facilitating greater convenience and continuity of treatment. Nonetheless, operational realities such as supply chain complexity, regulatory expectations for longitudinal evidence, and payer demands for demonstrable outcomes will determine which innovations achieve sustained adoption.

Companies that align scientific differentiation with pragmatic commercial execution-by investing in manufacturing resilience, generating robust real-world evidence, and building patient-centric support services-will be better positioned to realize the clinical and economic potential of their assets. Regional differences in regulatory and reimbursement frameworks require tailored access strategies, and trade policy dynamics add another layer of operational complexity that merits proactive mitigation. Ultimately, success in this evolving landscape will hinge on an integrated approach that combines clinical excellence, evidence-led value demonstration, and flexible distribution models that meet patients where they receive care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HAE Treatments Market, by Therapy Mechanism

  • 8.1. Bradykinin Receptor Antagonist
  • 8.2. C1 Inhibitor Replacement
    • 8.2.1. Plasma Derived C1 Inhibitor
    • 8.2.2. Recombinant C1 Inhibitor
  • 8.3. Kallikrein Inhibitor
    • 8.3.1. Ecallantide
    • 8.3.2. Lanadelumab

9. HAE Treatments Market, by Product Type

  • 9.1. On Demand
  • 9.2. Prophylactic

10. HAE Treatments Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Subcutaneous

11. HAE Treatments Market, by End User

  • 11.1. Clinic
  • 11.2. Home Healthcare
  • 11.3. Hospital

12. HAE Treatments Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. HAE Treatments Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy
  • 13.3. Specialty Pharmacy

14. HAE Treatments Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. HAE Treatments Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. HAE Treatments Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States HAE Treatments Market

18. China HAE Treatments Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Adverum Biotechnologies, Inc.
  • 19.6. Akari Therapeutics plc
  • 19.7. Alnylam Pharmaceuticals, Inc.
  • 19.8. Argenx SE
  • 19.9. AstraZeneca plc
  • 19.10. Attune Pharmaceuticals, Inc.
  • 19.11. BioCryst Pharmaceuticals, Inc.
  • 19.12. BioMarin Pharmaceutical Inc.
  • 19.13. CSL Behring GmbH
  • 19.14. Editas Medicine, Inc.
  • 19.15. F. Hoffmann-La Roche Ltd.
  • 19.16. Homology Medicines, Inc.
  • 19.17. IBio, Inc.
  • 19.18. KalVista Pharmaceuticals, Inc.
  • 19.19. Moderna, Inc.
  • 19.20. Novartis AG
  • 19.21. Pharming Group N.V.
  • 19.22. Regeneron Pharmaceuticals, Inc.
  • 19.23. Sangamo Therapeutics, Inc.
  • 19.24. Sarepta Therapeutics, Inc.
  • 19.25. Takeda Pharmaceutical Company Limited
  • 19.26. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL HAE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HAE TREATMENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HAE TREATMENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HAE TREATMENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HAE TREATMENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HAE TREATMENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HAE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HAE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HAE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HAE TREATMENTS MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONIST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HAE TREATMENTS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HAE TREATMENTS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HAE TREATMENTS MARKET SIZE, BY PLASMA DERIVED C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HAE TREATMENTS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HAE TREATMENTS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HAE TREATMENTS MARKET SIZE, BY RECOMBINANT C1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HAE TREATMENTS MARKET SIZE, BY ECALLANTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HAE TREATMENTS MARKET SIZE, BY ECALLANTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HAE TREATMENTS MARKET SIZE, BY ECALLANTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HAE TREATMENTS MARKET SIZE, BY LANADELUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HAE TREATMENTS MARKET SIZE, BY LANADELUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HAE TREATMENTS MARKET SIZE, BY LANADELUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HAE TREATMENTS MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HAE TREATMENTS MARKET SIZE, BY ON DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HAE TREATMENTS MARKET SIZE, BY ON DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HAE TREATMENTS MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HAE TREATMENTS MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HAE TREATMENTS MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HAE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HAE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HAE TREATMENTS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HAE TREATMENTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HAE TREATMENTS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HAE TREATMENTS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HAE TREATMENTS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HAE TREATMENTS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HAE TREATMENTS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HAE TREATMENTS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HAE TREATMENTS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HAE TREATMENTS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HAE TREATMENTS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HAE TREATMENTS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HAE TREATMENTS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HAE TREATMENTS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HAE TREATMENTS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HAE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HAE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HAE TREATMENTS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HAE TREATMENTS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HAE TREATMENTS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HAE TREATMENTS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HAE TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS HAE TREATMENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HAE TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 155. GCC HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 156. GCC HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 157. GCC HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GCC HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 182. G7 HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 183. G7 HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 184. G7 HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. G7 HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 191. NATO HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 192. NATO HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 193. NATO HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. NATO HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL HAE TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES HAE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA HAE TREATMENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA HAE TREATMENTS MARKET SIZE, BY THERAPY MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA HAE TREATMENTS MARKET SIZE, BY C1 INHIBITOR REPLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA HAE TREATMENTS MARKET SIZE, BY KALLIKREIN INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA HAE TREATMENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA HAE TREATMENTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA HAE TREATMENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA HAE TREATMENTS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA HAE TREATMENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)